Your browser doesn't support javascript.
loading
Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands.
Reesink, Daan J; van de Garde, Ewoudt M W; Peters, Bas J M; van der Nat, Paul B; Los, Maartje; Horenblas, Simon; van Melick, Harm H E.
Afiliación
  • Reesink DJ; Urology Department, St. Antonius Hospital, Koekoekslaan 1, 3435CM, Nieuwegein/Utrecht, The Netherlands. d.reesink@antoniusziekenhuis.nl.
  • van de Garde EMW; Clinical Pharmacy Department, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
  • Peters BJM; Clinical Pharmacy Department, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
  • van der Nat PB; Value Based Healthcare Department, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
  • Los M; Oncology Department, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
  • Horenblas S; Urology Department, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Melick HHE; Urology Department, St. Antonius Hospital, Koekoekslaan 1, 3435CM, Nieuwegein/Utrecht, The Netherlands.
Sci Rep ; 10(1): 15822, 2020 09 25.
Article en En | MEDLINE | ID: mdl-32978455
This retrospective study was performed to evaluate real-world oncological outcomes of patients treated with chemo-based therapy for muscle-invasive or metastatic bladder cancer (MIBC/mBC) and compare results to data from RCTs and other cohorts. Among 1578 patients diagnosed, 470 (30%) had MIBC/mBC. Median overall survival (mOS) for RC alone (47 months), first-line (13 months) and second-line (7 months) chemotherapy, and chemotherapy for recurrent disease (8 months) were similar to literature. Treatment with neoadjuvant and induction chemotherapy (NAIC) was only utilized in 9% of patients, and often in patients with poor disease status, resulting in a lower mOS compared to literature (35 and 20 months, respectively). Patients treated with chemotherapy had many adversities to treatment, with only 50%, 13%, 18% and 7% of patients in NAIC, first-line, salvage after RC, and second-line setting completing the full pre-planned chemotherapy treatment. Real-world data shows NAIC before RC is underutilized. Adversities during chemotherapy treatment are frequent, with many patients requiring dose reduction or early treatment termination, resulting in poor treatment response. Although treatment efficacy between RCTs and real-world patients is quite similar, there are large differences in baseline characteristics and treatment patterns. Possibly, results from retrospective studies on real-world data can deliver missing evidence on efficacy of chemotherapy treatment on older and 'unfit' patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de los Músculos / Terapia Neoadyuvante Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de los Músculos / Terapia Neoadyuvante Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido